UniSuper Management Pty Ltd Raises Stock Holdings in Solventum Co. (NYSE:SOLV)

UniSuper Management Pty Ltd raised its position in shares of Solventum Co. (NYSE:SOLV) by 13.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,509 shares of the company’s stock after purchasing an additional 3,192 shares during the quarter. UniSuper Management Pty Ltd’s holdings in Solventum were worth $1,751,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of SOLV. Modus Advisors LLC purchased a new stake in Solventum in the fourth quarter valued at approximately $25,000. Stonebridge Financial Group LLC acquired a new stake in Solventum during the 4th quarter valued at approximately $26,000. Crews Bank & Trust purchased a new stake in shares of Solventum in the 4th quarter valued at $32,000. True Wealth Design LLC increased its stake in shares of Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after acquiring an additional 471 shares during the period. Finally, Synergy Asset Management LLC purchased a new position in shares of Solventum during the fourth quarter worth $35,000.

Solventum Trading Down 1.0 %

Shares of NYSE:SOLV opened at $74.78 on Monday. The business’s 50 day moving average price is $75.51 and its 200-day moving average price is $71.87. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92. The firm has a market capitalization of $12.94 billion and a price-to-earnings ratio of 27.19. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Morgan Stanley increased their price target on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th. Mizuho raised their target price on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. The Goldman Sachs Group boosted their price target on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. Wells Fargo & Company raised their price objective on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Finally, Bank of America lifted their target price on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.